Physician profile
Mathew D Smith
NPI 1538260807
$2,079.84
in general payments reported to CMS, 2019-2025
34 companies · $532 in 2025
The $532 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $75.86 · 2021: $32.38 · 2022: $236 · 2023: $560 · 2024: $315 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074 · Travel and Lodging: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.79 |
| Travel and Lodging | $332.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $332.95 | 2023 | Da Vinci Surgical System |
| Astellas Pharma US INC | $318.82 | 2019-2025 | Veozah |
| Coloplast Corp | $221.28 | 2019-2025 | Altis |
| Hologic Sales and Service, LLC | $145.28 | 2022 | |
| Depuy Synthes Sales INC. | $141.41 | 2025 | Na |
| Medtronic, INC. | $129.45 | 2022-2024 | Interstim |
| Abbvie INC. | $126.48 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $78.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.97 | 2019-2020 | |
| Novo Nordisk INC | $41.43 | 2024-2025 | Wegovy |
| Lilly USA, LLC | $38.25 | 2024-2025 | Zepbound |
| Exeltis, USA INC. | $37.61 | 2025 | Slynd |
| Sumitomo Pharma America, INC. | $32.71 | 2025 | Myfembree |
| Pfizer INC. | $31.48 | 2020-2024 | |
| Ethicon US, LLC | $31.46 | 2024 | Ethicon, Evicel Fibrin Sealant (Human), Vistaseal |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $30.45 | 2025 | Arista |
| Biogen, INC. | $29.20 | 2025 | Zurzuvae |
| Allergan, INC. | $27.72 | 2019 | |
| Bausch Health US, LLC | $18.88 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.77 | 2023 | Opsumit |
| Lsi Solutions INC | $18.11 | 2024 | Fornisee |
| Takeda Pharmaceuticals U.S.A., INC. | $17.25 | 2019 | |
| Stryker Corporation | $16.57 | 2024 | Surgicount |
| Organogenesis INC. | $16.51 | 2024 | |
| Shield Therapeutics INC | $16.43 | 2025 | |
| Axonics, INC. | $16.23 | 2024 | Bulkamid, Axonics |
| Csl Behring | $13.58 | 2021 | |
| Covidien LP | $13.17 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.96 | 2019 | |
| Dysis Medical, INC. | $12.85 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.38 | 2019 | |
| Therapeuticsmd, INC. | $12.24 | 2020 | |
| Boston Scientific Corporation | $11.52 | 2020 | |
| Aspira Women'S Health INC | $9.52 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.